Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Murray, Utah Clinical Trials

A listing of Murray, Utah clinical trials actively recruiting patient volunteers.

RESULTS

Found (11) clinical trials

Control of Myopia Using Novel Spectacle Lens Designs

Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile myopia.

Phase N/A

3.19 miles

Learn More »

Efficacy and Safety Study of a Test Naproxen Sodium 220mg Tablet in Postoperative Dental Pain

This is a single-dose, randomized, double-blind, placebo- and active- controlled, parallel-group study to evaluate the analgesic onset, efficacy, and safety profile of 440 mg of naproxen sodium administered as two Test NPX 220 mg tablets compared with two commercial products and placebo over a twelve-hour period after third-molar extractions. Subjects ...

Phase

3.98 miles

Learn More »

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.

Phase

4.65 miles

Learn More »

Do you get migraines? Volunteers age 18 to 75 may qualify for a migraine research study if they: Have a history of migraine for at least 1 year Get at least 4 migraine days per month, on average Have tried 2 to 4 migraine prevention medications that did not work ...

Phase

4.65 miles

Learn More »

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of symptoms of depression, as assessed by ...

Phase

6.33 miles

Learn More »

GlaxoSmithKline's (GSK) Safety and Immunogenicity Study of GSK Meningococcal Group B and 13-valent Pneumococcal Vaccines Administered Together With Routine Infant Vaccines in Healthy Infants

This study will be divided into 3 timepoints: Epoch 1- Primary- From day 1 to day 301 Epoch 2-Secondary-From day 301 to day 331 Epoch 3-Safety follow up -From day 331 to study end (day 661) In addition to receiving the study vaccines, infants will also receive non-study vaccines such ...

Phase

6.54 miles

Learn More »

Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation

BACKGROUND AND SIGNIFICANCE: Importance and impact: It is becoming increasingly apparent that arterial endothelial dysfunction contributes significantly to the age-related downward spiral that includes mobility limitation, frailty, and ultimately cardiovascular disease (CVD) endothelial dysfunction has been documented to manifest in the coronary epicardial and resistance vasculature as well as the ...

Phase N/A

6.75 miles

Learn More »

Rucaparib in Nonmetastatic prOstAte With BRCAness

This is a single arm, open label, phase II trial to assess efficacy of rucaparib.

Phase

7.28 miles

Learn More »

Project: Every Child for Younger Patients With Cancer

PRIMARY OBJECTIVES: I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer. II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic ...

Phase N/A

7.35 miles

Learn More »

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

PRIMARY OBJECTIVES: I. To estimate the progression-free survival (PFS) of children >= 3 years of age with wingless-type MMTV integration site family (WNT)/WNT-driven average-risk medulloblastoma using reduced craniospinal radiotherapy (CSI) (18 Gray [Gy]) with a limited target volume boost to the tumor bed of 36 Gy for a total of ...

Phase

7.35 miles

Learn More »